
CPA Issues Statement of Support for New Labor Tariff Action
New duties on imports from dozens of countries take effect this week, closing the gap left after the Supreme Court struck down the President’s earlier tariff authority.
CPA CHAIRMAN, PRESIDENT OF ATLAS TOOL WORKS, INC.
Zachary Justin Mottl is the fourth generation of his family to own and operate Atlas Tool Works. The company, founded in 1918, is a world class precision manufacturing facility offering a broad array of metal manufacturing services. Key markets include: Defense and Aerospace, Medical, Telecom and Electronics, and Industrial products.
Â
Â
In his current role as President, Zach works not only to increase business with new and existing customers, but also to engage in outreach, develop strategy, and find operational improvements at Atlas and the family’s related businesses including Accushim Inc. and Abet Industries.
Zach is an advocate for the value and importance of domestic manufacturing in any healthy state or national economic model and has testified before Congress on several occasions.
Zach serves on many boards and organizations including, the Coalition for a Prosperous America (CPA), the Cyber Security Committee at MXD, and Illinois Military Economic Development Committee.

New duties on imports from dozens of countries take effect this week, closing the gap left after the Supreme Court struck down the President’s earlier tariff authority.

Companies making goods from the Department of War (DoW) will now need much clearer visibility into their supply chains, especially if a product they make or buy includes critical minerals.

Trade structured to support production raises productivity, and rising productivity raises the incomes that fund consumption durably, out of earnings instead of borrowing. That is the only durable answer to the cost-of-living crisis: paychecks that can carry the price of housing, healthcare, and childcare.

For years, the most critical link in our drug supply chain — the upstream chemistry — has been invisible to our own regulators. A medicine finished in Europe is not necessarily a European medicine, and this rule finally begins to expose that fiction.